Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$1.16 +1.3%	$1.23	$0.66 ▼ $5.75	$132.37M	2.18	2.09 million shs	248,885 shs
KROS Keros Therapeutics	$14.28 -1.3%	$14.06	$9.12 ▼ $72.37	$579.89M	1.26	1.03 million shs	127,455 shs
TYRA Tyra Biosciences	$10.88 -2.5%	$10.02	$6.42 ▼ $29.60	$577.67M	1.07	312,980 shs	39,569 shs
ZVRA Zevra Therapeutics	$10.86 -1.2%	$10.01	$5.95 ▼ $13.16	$593.28M	1.97	629,334 shs	95,405 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	-2.56%	-10.94%	+1.79%	-8.06%	-77.78%
KROS Keros Therapeutics	-0.07%	+0.28%	+8.39%	-0.69%	-71.83%
TYRA Tyra Biosciences	-0.45%	+3.15%	+16.51%	+6.39%	-48.31%
ZVRA Zevra Therapeutics	+1.67%	-6.63%	+24.74%	+43.85%	+99.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FATE Fate Therapeutics	3.8504 of 5 stars	3.1	1.0	4.7	3.3	1.7	0.6
KROS Keros Therapeutics	2.2486 of 5 stars	3.3	1.0	0.0	3.4	3.3	0.0
TYRA Tyra Biosciences	3.0669 of 5 stars	3.5	5.0	0.0	1.5	3.3	0.0
ZVRA Zevra Therapeutics	3.2341 of 5 stars	3.6	5.0	0.0	4.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.13	Hold	$3.83	231.89% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.56	114.03% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	183.52% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$23.71	118.46% Upside

Current Analyst Ratings Breakdown

Latest FATE, ZVRA, TYRA, and KROS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 7/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$13.34M	9.93	N/A	N/A	$2.80 per share	0.41
KROS Keros Therapeutics	$3.55M	163.35	N/A	N/A	$14.11 per share	1.01
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$6.78 per share	N/A
ZVRA Zevra Therapeutics	$23.61M	25.14	N/A	N/A	$0.74 per share	14.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
KROS Keros Therapeutics	-$187.35M	-$0.18	N/A	N/A	2.62	1.96%	0.75%	0.69%	8/6/2025 (Estimated)
TYRA Tyra Biosciences	-$86.48M	-$1.63	N/A	N/A	N/A	N/A	-26.90%	-25.54%	8/6/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	54.28	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest FATE, ZVRA, TYRA, and KROS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.34	N/A	N/A	N/A	$1.16 million	N/A
8/12/2025	Q2 2025	ZVRA Zevra Therapeutics	$0.65	N/A	N/A	N/A	$22.49 million	N/A
8/6/2025	Q2 2025	KROS Keros Therapeutics	-$1.13	N/A	N/A	N/A	$3.83 million	N/A
8/6/2025	Q2 2025	TYRA Tyra Biosciences	-$0.53	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
5/6/2025	Q1 2025	KROS Keros Therapeutics	-$0.01	$3.62	+$3.63	$3.62	$84.62 million	$211.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	8.81	8.81
KROS Keros Therapeutics	N/A	19.29	19.29
TYRA Tyra Biosciences	N/A	22.78	22.78
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
KROS Keros Therapeutics	71.56%
TYRA Tyra Biosciences	84.14%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	5.51%
KROS Keros Therapeutics	20.60%
TYRA Tyra Biosciences	15.20%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
KROS Keros Therapeutics	100	40.62 million	32.25 million	Optionable
TYRA Tyra Biosciences	20	53.09 million	45.02 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

FATE, ZVRA, TYRA, and KROS Headlines

Recent News About These Companies

What is William Blair's Estimate for ZVRA FY2025 Earnings?

5 hours ago | marketbeat.com

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

July 28 at 6:00 AM | globenewswire.com

Readystate Asset Management LP Purchases 616,370 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

July 23, 2025 | marketbeat.com

AIGH Capital Management LLC Has $10.77 Million Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

July 22, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Rating Lowered to "Buy" at Wall Street Zen

July 22, 2025 | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Downgraded to Buy Rating by Wall Street Zen

July 20, 2025 | marketbeat.com

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

July 18, 2025 | globenewswire.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.

July 17, 2025 | marketbeat.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...

July 16, 2025 | finanznachrichten.de

Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice

July 16, 2025 | zacks.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16, 2025 | zacks.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

July 16, 2025 | globenewswire.com

Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C

July 16, 2025 | quiverquant.comQ

Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?

July 16, 2025 | marketbeat.com

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

July 16, 2025 | marketbeat.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

July 15, 2025 | finance.yahoo.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

July 15, 2025 | zacks.com

Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)

July 15, 2025 | zacks.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Buy" from Analysts

July 15, 2025 | marketbeat.com

Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings

July 14, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen

July 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, ZVRA, TYRA, and KROS Company Descriptions

Fate Therapeutics NASDAQ:FATE

$1.16 +0.02 (+1.32%)

As of 11:00 AM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Keros Therapeutics NASDAQ:KROS

$14.29 -0.18 (-1.25%)

As of 10:59 AM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Tyra Biosciences NASDAQ:TYRA

$10.88 -0.28 (-2.47%)

As of 11:00 AM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Zevra Therapeutics NASDAQ:ZVRA

$10.86 -0.14 (-1.23%)

As of 11:00 AM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time